Medicago announces poster presentation at the IDSA Seasonal and Pandemic Influenza 2009 meeting

    QUEBEC CITY, Jan. 27 /CNW/ - Medicago Inc. (TSX-V : MDG) (the "Company"),
today announced that its abstract has been selected for a poster presentation
at the Infectious Diseases Society of America (IDSA) Seasonal and Pandemic
Influenza 2009 meeting, held in Washington, DC from February 2-3, 2009. Dr.
Sonia Trépanier will present highlights of the Company's development of
Influenza vaccines generated from plant-made Virus-Like Particles ("VLP") and
the potential of its proprietary manufacturing technology to address global
pandemic influenza supply challenges.
    The creation of vaccines for Avian Influenza in VLPs is a newer vaccine
approach that is rapidly gaining recognition. This technology was recently
selected by the Cleveland Clinic as one of the Top 10 Medical Innovation for
2009. VLPs have several advantages over traditional flu vaccines: they are
more rapid to develop, produce, and manufacture. Furthermore, a live virus is
not needed to produce a VLP vaccine, manufacturers only require the genetic
sequence of the virus.
    Poster Presentation: "Innovative H5N1 Virus-Like Particles: a Unique
Combination of Product and Manufacturing Solution", Trépanier S., Landry N.,
Guay J.M., D'Aoust M.A., Dargis M. and Vézina L.P., Monday February 2, 4:30
p.m. to 6:30 p.m., The Ritz-Carlton, Salon 1.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at

    Forward Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release.

    %SEDAR: 00023641E

For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Medicago, Inc., Arianna Vanin, Director, Investor
Relations & Communications, (514) 796-3993

Organization Profile

Medicago Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890